Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

9.41USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$9.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
447,223
52-wk High
$11.54
52-wk Low
$1.17

Chart for

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $244.81
Shares Outstanding(Mil.): 42.58
Dividend: --
Yield (%): --

Financials

  ECYT.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.01 -- --
ROI: -31.67 1.58 14.38
ROE: -31.86 2.41 16.07

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board

* ENDOCYTE NOMINATES DAWN SVORONOS FOR ELECTION TO ITS BOARD OF DIRECTORS AND ANNOUNCES OTHER BOARD DEVELOPMENTS

15 Mar 2018

BRIEF-Endocyte Says ‍In Connection With Machado's Election, Board Increased Size To 11 Members​

* ENDOCYTE INC SAYS ‍IN CONNECTION WITH MACHADO'S ELECTION, BOARD INCREASED SIZE OF BOARD FROM 10 TO 11 MEMBERS - SEC FILING​ Source text: (http://bit.ly/2FKviW0) Further company coverage:

02 Mar 2018

BRIEF-Endocyte Announces Proposed Public Offering Of Common Stock

* ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

28 Feb 2018

BRIEF-Endocyte Inc Appoints Patrick Machado To Its Board

* ENDOCYTE APPOINTS PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

27 Feb 2018

BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results

* ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

26 Feb 2018

BRIEF-Endocyte And ITM Announce Supply Agreement

* ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL

26 Feb 2018

BRIEF-‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6

* ‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​ Source text: [http://bit.ly/2A4glhH] Further company coverage:

16 Nov 2017

BRIEF-Endocyte Q3 loss per share $0.55

* Q3 loss per share $0.55 Source text for Eikon: Further company coverage:

06 Nov 2017

Earnings vs. Estimates